- Home
- EHLD vs CLRB Comparison
EHLD vs CLRB Comparison
Compare EHLD & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHLD
- CLRB
- Stock Information
- Founded
- EHLD 2024
- CLRB 2002
- Country
- EHLD Greece
- CLRB United States
- Employees
- EHLD N/A
- CLRB N/A
- Industry
- EHLD
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- EHLD
- CLRB Health Care
- Exchange
- EHLD NYSE
- CLRB Nasdaq
- Market Cap
- EHLD 17.2M
- CLRB 14.2M
- IPO Year
- EHLD N/A
- CLRB N/A
- Fundamental
- Price
- EHLD $7.82
- CLRB $5.09
- Analyst Decision
- EHLD
- CLRB Hold
- Analyst Count
- EHLD 0
- CLRB 2
- Target Price
- EHLD N/A
- CLRB N/A
- AVG Volume (30 Days)
- EHLD 14.9K
- CLRB 169.8K
- Earning Date
- EHLD 08-15-2025
- CLRB 08-12-2025
- Dividend Yield
- EHLD 7.16%
- CLRB N/A
- EPS Growth
- EHLD N/A
- CLRB N/A
- EPS
- EHLD 4.74
- CLRB N/A
- Revenue
- EHLD $14,687,504.00
- CLRB N/A
- Revenue This Year
- EHLD N/A
- CLRB N/A
- Revenue Next Year
- EHLD N/A
- CLRB N/A
- P/E Ratio
- EHLD $1.65
- CLRB N/A
- Revenue Growth
- EHLD N/A
- CLRB N/A
- 52 Week Low
- EHLD $3.83
- CLRB $4.36
- 52 Week High
- EHLD $12.80
- CLRB $73.80
- Technical
- Relative Strength Index (RSI)
- EHLD N/A
- CLRB 38.98
- Support Level
- EHLD N/A
- CLRB $4.89
- Resistance Level
- EHLD N/A
- CLRB $5.85
- Average True Range (ATR)
- EHLD 0.00
- CLRB 0.33
- MACD
- EHLD 0.00
- CLRB 0.17
- Stochastic Oscillator
- EHLD 0.00
- CLRB 38.21
About EHLD EUROHOLDINGS LTD
Euroholdings Ltd is a provider of shipping transportation services. The company specializes in the ownership of vessels. The fleet of the company consists of containerships that transport container boxes providing scheduled service between ports.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.